Objective: This study aimed to compare the efficacy and safety of neoadjuvant chemotherapy with TAC and TP regimens of triple negative breast cancer(TNBC). Methods: A total of 102 patients with TNBC were confirmed by ...Objective: This study aimed to compare the efficacy and safety of neoadjuvant chemotherapy with TAC and TP regimens of triple negative breast cancer(TNBC). Methods: A total of 102 patients with TNBC were confirmed by histopathology. They were divided into TAC group(52 cases) and TP group(50 cases). Group TAC: Docetaxel 75 mg/m2 or paclitaxel(taxol liposome) 135 mg/m2 on d1, pirarubicin 40 mg/m2 or epirubicin 75 mg/m2 on d2, cyclophosphamide 600 mg/m2 on d1; Group TP: Docetaxel 75 mg/m2 or paclitaxel(taxol liposome) 135 mg/m2 on d1, cisplatin 30 mg/m2 on d2–d4, with 21 days as a cycle. All patients underwent operation after 2–4 cycles of chemotherapy. The short-term effects and toxic and adverse effects were evaluated. Results: In TAC group, 5 cases(9.6%) had pathological complete release(pCR), 35 cases(67.3%) partial release(PR), 9 cases(17.3%) stable disease(SD), and the response rate(RR) was 76.9%. In TP group, 4 cases(8%) had pCR, 32 cases(64%) PR, 5 cases(10%) SD, and RR was 72%. In 102 patients, 12 patients with tumor progression after 2 cycles of chemotherapy, included 3 cases in TAC group, 9 cases in TP group. In TAC group, 2 cases occurred atrial premature contraction; while 3 cases developed grade 2 renal injury in TP group. In TAC group, grade 3–4 hematologic toxicity and alopecia was significantly higher than that in TP group, but grade 3–4 gastrointestinal reaction rate in TP group was significantly higher than TAC group. Conclusion: TAC and TP regimens all had certain efficacy in the neoadjuvant chemotherapy for TNBC, and the toxicity reactions can be tolerated.展开更多
文摘Objective: This study aimed to compare the efficacy and safety of neoadjuvant chemotherapy with TAC and TP regimens of triple negative breast cancer(TNBC). Methods: A total of 102 patients with TNBC were confirmed by histopathology. They were divided into TAC group(52 cases) and TP group(50 cases). Group TAC: Docetaxel 75 mg/m2 or paclitaxel(taxol liposome) 135 mg/m2 on d1, pirarubicin 40 mg/m2 or epirubicin 75 mg/m2 on d2, cyclophosphamide 600 mg/m2 on d1; Group TP: Docetaxel 75 mg/m2 or paclitaxel(taxol liposome) 135 mg/m2 on d1, cisplatin 30 mg/m2 on d2–d4, with 21 days as a cycle. All patients underwent operation after 2–4 cycles of chemotherapy. The short-term effects and toxic and adverse effects were evaluated. Results: In TAC group, 5 cases(9.6%) had pathological complete release(pCR), 35 cases(67.3%) partial release(PR), 9 cases(17.3%) stable disease(SD), and the response rate(RR) was 76.9%. In TP group, 4 cases(8%) had pCR, 32 cases(64%) PR, 5 cases(10%) SD, and RR was 72%. In 102 patients, 12 patients with tumor progression after 2 cycles of chemotherapy, included 3 cases in TAC group, 9 cases in TP group. In TAC group, 2 cases occurred atrial premature contraction; while 3 cases developed grade 2 renal injury in TP group. In TAC group, grade 3–4 hematologic toxicity and alopecia was significantly higher than that in TP group, but grade 3–4 gastrointestinal reaction rate in TP group was significantly higher than TAC group. Conclusion: TAC and TP regimens all had certain efficacy in the neoadjuvant chemotherapy for TNBC, and the toxicity reactions can be tolerated.
